LENZ Therapeutics Inc.
LENZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$168.06M
Close$
$1.06
79% downside
Current Fair Value
79% downsideOvervalued by 79% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $168.06 Million |
|---|---|
| Enterprise Value | $143.52 Million |
| Dividend Yield | $14.42 (-) |
| Earnings per Share | $-2.85 |
| Beta | 1.62 |
| Outstanding Shares | 31,352,702 |
Return
| Return on Equity | -44.22% |
|---|---|
| Return on Assets | -39.99% |
| Return on Invested Capital | -48.01% |
Valuation & Multiples
| P/E Ratio | -1.49 |
|---|---|
| PEG | -0.81 |
| Price to Sales | - |
| Price to Book Ratio | 0.72 |
| Enterprise Value to Revenue | 6.84 |
| Enterprise Value to EBIT | -1.21 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-1.05
Average shareholder expectationRevenue Estimate
$2.38 M
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-1.07
Average shareholder expectationRevenue Estimate
$7.12 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 231.29% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 17.46%▼ 88.24% |
|---|---|
| Total Invested | $31.09M▼ 89.75% |
| Investors Holding | 45▼ 106.00% |
ESG Score
No data
About LENZ Therapeutics Inc.
119 employeesgraphite bio is a next-generation gene editing company focused on the development of first-in-class therapies for patients suffering from life-threatening genetic diseases. the company’s platform harnesses the natural cellular process of...